Ono Pharmaceutical Co., Ltd. (4528.T) JPX

Currency In JPY

Key Executives

Name	Title	Pay	Year Born
Gyo Sagara	Chief Executive Officer & Chairman of the Board	142M	1958
Toshihiro Tsujinaka	Corp Sr Ex Off, Chief CMC & Prod, Dig Tech, Glob Qual, Bus Trans Dept Off, Bus Des/Chief Off and Dir	78M	1964
Toichi Takino	President, Chief Operating Officer & Representative Director	102M	1968
Tatsuya Okamoto	Corporate Officer & Executive Director of Clinical Development, Oncology Clinical Development Div.	0	N/A
Shinji Takai	Corporate Officer & Head of Medical Affairs	0	N/A
Thomas Lechner	Vice President of Medical Affairs	0	N/A
Akira Takada	Corporate Executive Officer & Executive Director of CMC & Production	0	N/A
Hiroyuki Takahashi	Director of Oncology Business Division	0	N/A
Satoshi Takahagi	Senior Director of EHS Promotion & Corporate Officer	0	N/A
Hiromu Habashita	Corporate Officer, Senior Vice President, Discovery & Research	0	N/A
Takehiro Yamada	Corporate Officer & Head of Risk and Compliance Management Department	0	N/A
Masayuki Tanigawa	Corporate Officer, Executive VP of Business Strategy & VP of License	0	N/A
Masaki Ito	Corporate Executive Officer and Div. Director of Corporate Strategy, Planning & Bus. Management Div.	0	N/A

Name

Title

Pay

Year Born

Gyo Sagara

Chief Executive Officer & Chairman of the Board

142M

1958

Toshihiro Tsujinaka

Corp Sr Ex Off, Chief CMC & Prod, Dig Tech, Glob Qual, Bus Trans Dept Off, Bus Des/Chief Off and Dir

78M

1964

Toichi Takino

President, Chief Operating Officer & Representative Director

102M

1968

Tatsuya Okamoto

Corporate Officer & Executive Director of Clinical Development, Oncology Clinical Development Div.

N/A

Shinji Takai

Corporate Officer & Head of Medical Affairs

N/A

Thomas Lechner

Vice President of Medical Affairs

N/A

Akira Takada

Corporate Executive Officer & Executive Director of CMC & Production

N/A

Hiroyuki Takahashi

Director of Oncology Business Division

N/A

Satoshi Takahagi

Senior Director of EHS Promotion & Corporate Officer

N/A

Hiromu Habashita

Corporate Officer, Senior Vice President, Discovery & Research

N/A

Takehiro Yamada

Corporate Officer & Head of Risk and Compliance Management Department

N/A

Masayuki Tanigawa

Corporate Officer, Executive VP of Business Strategy & VP of License

N/A

Masaki Ito

Corporate Executive Officer and Div. Director of Corporate Strategy, Planning & Bus. Management Div.

N/A

Description

Ono Pharmaceutical Co., Ltd., along with its affiliated companies, is engaged in the global development, manufacturing, procurement, and sale of a diverse range of pharmaceutical products and diagnostic tools. Its diverse oncology portfolio includes OPDIVO intravenous infusions, KYPROLIS for injection, MEKTOVI, VELEXBRU, and ADLUMIZ tablets, along with BRAFTOVI capsules, all prescribed for various malignant tumors. It also provides EMEND capsules and PROEMEND intravenous injections to alleviate chemotherapy-induced nausea and vomiting, and DEMSER capsules for managing symptoms in pheochromocytoma patients. Beyond oncology, the company's offerings span multiple therapeutic areas. For metabolic disorders, it supplies GLACTIV and FORXIGA tablets for type 2 diabetes. Cardiovascular health is supported by ONOACT injections for tachyarrhythmia, CORALAN for chronic heart failure, and OPALMON tablets addressing peripheral circulatory disorders. Autoimmune conditions like rheumatoid arthritis are treated with ORENCIA injections. Neurological therapies include RIVASTACH patches for Alzheimer's disease and ONGENTYS tablets for Parkinson's disease. Other notable products are PARSABIV intravenous injections for dialysis patients, STAYBLA tablets for overactive bladder, ONON capsules and dry syrups for bronchial asthma and allergic rhinitis, and RECALBON tablets for osteoporosis, with JOYCLU intra-articular injection available to improve joint function. Moreover, the company is heavily invested in research and development, with a pipeline targeting a wide array of diseases. This includes various malignancies such as esophageal, urothelial, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular, pancreatic, biliary tract, gastric, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, and virus-positive/negative solid tumors, as well as primary central nervous system lymphoma. Beyond cancer, its developmental efforts extend to myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative and autoimmune disorders, narcolepsy, and thrombosis. Established in 1717, the company maintains its corporate headquarters in Osaka, Japan.